China's biopharmaceutical industry is undergoing a landmark transformation, emerging from a period of profound recalibration to establish itself as a global powerhouse. Propelled by its talent, patient access, cost-efficient infrastructure, and catalysed by comprehensive government policies aimed at supporting the innovative drug value chain, the sector is experiencing a broad-based resurgence, with results beginning to show in earnings and valuations in the first half of the year. The journey, however, is just beginning, fueled by the impending global patent cliff and its strong value proposition: delivering high-quality, innovative medicines at an accelerated pace. This capability ensures China's biopharma sector an indispensable player in the global market, even in the face of possible geopolitical headwinds. In this article, we discuss about the leading innovators in the homegrown biotech landscape—companies well-represented in our Premia China New Economy ETF (3173/9173 HK) and Premia China STAR50 ETF (3151/9151/83151 HK), which have outperformed multiple benchmarks year-to-date and will continue to drive alpha returns for global investors, propelled by a revaluation trend driven by domestic policy tailwinds, strong external partnerships and a rising market value.

Oct 03, 2025

Vietnam stands out as Asia’s best-performing equity market in 2025, fueled by earnings recovery, policy support, and surging public investment. More importantly, Resolution 68 marks the country’s boldest reform agenda since Doi Moi—streamlining bureaucracy, empowering the private sector, and deepening capital markets—creating structural upside beyond cyclical drivers. With infrastructure projects worth over 10% of GDP, robust FDI inflows, and the potential MSCI/FTSE upgrade unlocking sizable foreign flows, Vietnam offers a rare blend of near-term catalysts and long-term growth. In this article, our Partner & Co-CIO David Lai discusses how Premia Vietnam ETF offers investors a diversified, transparent, and cost-effective vehicle that has consistently outperformed active peers—positioning portfolios to capture one of the most compelling reform-driven growth stories in emerging Asia.

Sep 12, 2025

China’s A-share market is turning the corner, as investors looking past weak data and piling back into growth. Signs of rotation by domestic investors from bank deposits and safe haven assets to equity market increasingly validate investor confidence is back. Policy momentum, attractive valuations, and light foreign positioning are fueling a durable rally, echoing the 2016 supply-side reform. Leadership is shifting decisively to innovation-driven sectors — from biotech and healthcare to solar, AI, and robotics — where structural growth and global relevance are accelerating, and are expected to be important focus in China’s upcoming 15th Five Year Plan. In this article, our Partner & Co-CIO David Lai and Portfolio Manager Alex Chu discuss why, with sentiment improving and risk appetite returning, the best way to play China’s new growth cycle is through high-conviction exposure via Premia’s STAR50 ETF and CSI Caixin New Economy ETF.

Aug 26, 2025

China's STAR Market appears poised for a major growth surge, fueled by a wave of innovative robotics companies set to launch their initial public offerings. Leading industry players, including Unitree, Zhiyuan Robot, Jaka Robotics, Fine Motion Tech, and Sichuan Tianlian Robot, are all in the IPO pipeline. In this article, we will introduce these firms that are at the forefront of technological innovation in humanoid and industrial robotics, whose momentum is expected to accelerate, driven by ongoing industry innovation and the favorable policy tailwinds of China's upcoming 15th Five-Year Plan.

Aug 25, 2025

Even for the prepared and informed, at the recent World Artificial Intelligence Conference (WAIC 2025), China has still taken the world by surprise with the debutante of its fleet of over 150 AI-powered humanoid robots. Indeed 2025 marks the beginning of commercialization and production of these futuristic robots, now made reality. While humanoid robots have captured the imagination of the popular media, there has been a more important revolution in the broader robotics industry, where China has emerged, as the global powerhouse, just as it did in renewable energy and electric vehicles. In this article, we discuss how humanoid industrial robots have quickly been integrated in China’s production lines, filling the productivity void from the country’s aging population, while further driving down the manufacturing production costs with high degree of automation with these embodied AI applications.

Aug 06, 2025